total intravenous anesthesia
Conditions
Interventions
fospropofol disodium:fospropofol disodium 20mg/kg + sufentanil 0.1ug/kg, pump infusion of fospropofol disodium 10-20 mg/kg/h
propofol:Propofol 2mg / kg + sufentanyl 0.1 ug / kg, pump injection of propofol 4-12 mg / kg / h
Sponsors
The Affiliated Suzhou Hospital of Nanjing Medical University
Eligibility
Sex/Gender
Female
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: Age: 18 to 65 years, female, (BMI): 18.5 to 30 kg/m^2; ASA I and II; Subjects undergoing elective hysteroscopy surgery; Non-acute hospitalized subject with appropriate preoperative preparation; Vital signs: respiratory rate 10 ~24 beats / min; air oxygen saturation (SpO 2) >=95%; systolic blood pressure (SBP)>=90mmHg and =60mmHg and=55 and<=100 beats / min; Understanding the process and methods of the study, voluntarily participated in it and signed the informed consent form.
Exclusion criteria
Exclusion criteria: (1) Patients with contraindications to general anaesthesia or a history of anesthesia accidents; (2) Have known or suspected allergy or contraindications to propofol injection and opioids; (3) Combined with brain loss, intracranial hypertension, stroke, unstable angina pectoris, myocardial infarction; (4) Respiratory insufficiency, obstructive pulmonary disease, presence of difficult airway or being judged as difficult tracheal intubation (modified horse score grade III or IV) (5) uncontrolled diabetes mellitus or hypertension; (6) severe liver dysfunction or severe renal insufficiency; (7) History of alcohol abuse or drug dependence; (8) Abuse or long-term application of anesthesia, sedation and analgesic drugs; (9) A previous history of mental illness; (10) Those who have participated in any drug clinical trial within 1 month before the screening; (11) Subjects for whom the investigator considers any other factor inappropriate to participate in this trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| QoR15 score at 24 hours postoperatively; | — |
Secondary
| Measure | Time frame |
|---|---|
| QoR15 score;vital signs;Time-related indicators;Dosage of drugs used;satisfaction; | — |
Countries
China
Contacts
Public ContactGu chengyong
The Affiliated Suzhou Hospital of Nanjing Medical University
Outcome results
None listed